<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/63E84433-DCF0-43B3-9DC6-108921625A22"><gtr:id>63E84433-DCF0-43B3-9DC6-108921625A22</gtr:id><gtr:name>Van Andel Institute</gtr:name><gtr:address><gtr:line1>Van Andel Institute</gtr:line1><gtr:line2>333 Bostwick Avenue NE</gtr:line2><gtr:postCode>MI 49503</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/FAE32A25-51D3-49EF-998F-281B3A47C212"><gtr:id>FAE32A25-51D3-49EF-998F-281B3A47C212</gtr:id><gtr:name>Helmholtz Association of German Research Centres</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:department>Cambridge Institute for Medical Research</gtr:department><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/63E84433-DCF0-43B3-9DC6-108921625A22"><gtr:id>63E84433-DCF0-43B3-9DC6-108921625A22</gtr:id><gtr:name>Van Andel Institute</gtr:name><gtr:address><gtr:line1>Van Andel Institute</gtr:line1><gtr:line2>333 Bostwick Avenue NE</gtr:line2><gtr:postCode>MI 49503</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/FAE32A25-51D3-49EF-998F-281B3A47C212"><gtr:id>FAE32A25-51D3-49EF-998F-281B3A47C212</gtr:id><gtr:name>Helmholtz Association of German Research Centres</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/2BE9A55F-1542-427E-877B-EF4684BF041C"><gtr:id>2BE9A55F-1542-427E-877B-EF4684BF041C</gtr:id><gtr:firstName>Ermanno</gtr:firstName><gtr:surname>Gherardi</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G9704528"><gtr:id>6BF91CEB-8A7C-4DFE-8039-02F77AEAE3F4</gtr:id><gtr:title>Engineering growth factors for therapy</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G9704528</gtr:grantReference><gtr:abstractText>Complex organisms are composed of bilions of cells which specialize to form different organs such as the brain, the heart, the liver, etc. How do cells decide to become brain cells or heart cells or liver cells ? Cells exchange information with each other through special chemicals which travel from cell to cell and instruct them how to behave, for example whether to divide or not or whether to develop a particular function. In cancer, cells can send the wrong signalsother cells or may not be able to read correctly the signals they receive from normal cells. As a result cancer cells carry out the wrong instructions, for example they may divide when they should not or migrate where they should not. The aim of this research programme is to study a particular type of cell signal and understand its chemical structure. This may lead to a better understanding of cell communication in complex organisms and lead to the possibility of engineering forms of this chemical that could correct the behaviour of cancer cells.</gtr:abstractText><gtr:technicalSummary>This application is for renewal of an MRC Programme Grant for studies on growth factors and receptors and principally on the hgf/sf - met signalling system . Work over the last few years has shown that the growth factor hgf/sf and its receptor met are essential for vertebrate development but it is now clear that these molecules also play important roles in post-natal life in tissue regeneration and in cancer. During the tenure of the current Programme Grant we have solved the structure of nk1, a receptor binding fragment of hgf/sf and produced a domain structure of the met receptor through deletion analysis. We have also engineered both hgf/sf and nk1 for therapy and developed a general genetic strategy for engineering protein affinity and/or specificity that may have a broad impact for the development of protein-based therapies. I propose to extend the work on the met receptor in order to obtain crystal structures of the ligand-binsing domain alone and in complex with nk1 or hgf/sf. I also propose to engineer nk1 and met antibodies as receptor antagonists for cancer therapy. This Programme has a strong foundation in the work accomplished and may be extended to other growth factor - receptor systems subject to a successful outcome of the above objectives.</gtr:technicalSummary><gtr:fund><gtr:end>2008-10-31</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>1997-10-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>2103225</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Van andel Research Institute (VARI)</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Structural Sciences</gtr:department><gtr:description>Engineering HGF/SF fragments as receptor antagonists</gtr:description><gtr:id>C1F2147C-4236-4529-ACF4-1AC5526FB366</gtr:id><gtr:impact>A joint publication.</gtr:impact><gtr:partnerContribution>Dr Eric Xu and his collaborators have been addressing the structure and function of two fragments of HGF/SF (NK1 and NK2) in order to understand the basis for receptor activation or antagonism. They have expressed these proteins and several mutants of them in bacteria and determined crystal structures of both NK1 and a mutant variant of NK2. These studies established a requirement for dimerisation for agonistic activity and offered a way to engineer both NK1 and NK2 as MET antagonists.</gtr:partnerContribution><gtr:piContribution>Our laboratory has been interested in the structure of HGF/SF and several truncated variants of HGF/SF, such as NK1 and NK2, for several years. Our work and initial independent studies by Dr Xu and his colleagues at the Van Andel Institute appeared to be complementary and formed the basis for a collaborative programme of work in which we suceeded in developing protein antagonists of the MET receptor using the natural ligand HGF/SF as a starting point.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Helmholtz Association of German Research Centres</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:department>Helmholtz Centre for Infection Research (HZI)</gtr:department><gtr:description>Structure of InlB-MET complexes</gtr:description><gtr:id>9C9E53DF-6360-4E1A-BE78-C2E857673D50</gtr:id><gtr:impact>A joint publication.</gtr:impact><gtr:partnerContribution>Dr Dirk Heinz's laboratory has worked for a number of years on the structure and functional of proteins of L monocytogenes involved in pathogenecity. One of these proteins, known as InlB, is a ligand for the MET receptor, a protein studied in our laboratory. Dr Heinz's and his colleagues produced InlB variants andd crystallised the complex between InlB321 and a fragment of the MET ectodomain</gtr:partnerContribution><gtr:piContribution>Our laboratory has contributed MET constructs and MET-expressing cell lines to the project. It also carried physico-chemical analysis of ligand-receptor complexes by analytical ultracentrifugation and biological studies aimed at defining the activity of the InlB ligands and validating the conclusions of the crystal structure.</gtr:piContribution><gtr:sector>Public</gtr:sector></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>469889</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Programme Grant</gtr:description><gtr:end>2011-10-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>21CD47DE-BAFD-4109-B0D4-35D8E23EF2C0</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-10-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>A method for producing soluble fragments of the ectodomain of the MET receptor and the use of such fragments in order to screen for agents that may block the binding of HGF/SF to MET.</gtr:description><gtr:id>77787139-FCC4-40AE-A5BF-5D4D1247A178</gtr:id><gtr:impact>None yet.</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:patentId>US2007037209</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>Soluble fragments of the MET receptor</gtr:title><gtr:yearProtectionGranted>2007</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>Variants of the NK1 fragment of HGF/SF that exhibit strong agonistic activity.</gtr:description><gtr:id>06ABE870-0BF9-4B31-970B-8BB3C6C5E110</gtr:id><gtr:impact>Strong pre-clinical data obtained in mouse models of liver and sking regeneration.</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:patentId>US7179786</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>Protein variants</gtr:title><gtr:yearProtectionGranted>2007</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Linker mutants of the NK1 fragment of HGF/SF with receptor antagonistic activity.</gtr:description><gtr:id>531CE3AC-88F8-46F8-8312-B2B1CBE31F56</gtr:id><gtr:impact>These protein variants have significant receptor antagonistic activity and are being explored for their activity as inhibitors of the MET receptor.</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Growth factor variants</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2010</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>A set of stable transfectants of the Lec variants of CHO cells producing several soluble truncations of the MET receptor ectodomain.</gtr:description><gtr:id>1CFD53C4-AB70-4171-9D37-4D4479F04726</gtr:id><gtr:impact>Used for the production of anti-MET antibodies.</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>MET-expressing mammalian cell lines</gtr:title><gtr:type>Cell line</gtr:type><gtr:yearFirstProvided>2006</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/FCBB2E42-7BF5-42BE-8EBF-2BE4588D41BC"><gtr:id>FCBB2E42-7BF5-42BE-8EBF-2BE4588D41BC</gtr:id><gtr:title>Computer-assisted mass spectrometric analysis of naturally occurring and artificially introduced cross-links in proteins and protein complexes.</gtr:title><gtr:parentPublicationTitle>The FEBS journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/d1816989312c19f4ff179767b4cb51a4"><gtr:id>d1816989312c19f4ff179767b4cb51a4</gtr:id><gtr:otherNames>de Koning LJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>1742-464X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/5081E8E8-E5A5-410D-8259-163C7FF5A7B7"><gtr:id>5081E8E8-E5A5-410D-8259-163C7FF5A7B7</gtr:id><gtr:title>Structure of the human receptor tyrosine kinase met in complex with the Listeria invasion protein InlB.</gtr:title><gtr:parentPublicationTitle>Cell</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/968f5a51fae20554b7dbe6e06097a10c"><gtr:id>968f5a51fae20554b7dbe6e06097a10c</gtr:id><gtr:otherNames>Niemann HH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0092-8674</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/5A2510BD-67FF-4951-9A8C-483ECE9D443E"><gtr:id>5A2510BD-67FF-4951-9A8C-483ECE9D443E</gtr:id><gtr:title>Crystal structure of an engineered YopM-InlB hybrid protein.</gtr:title><gtr:parentPublicationTitle>BMC structural biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/b1c9c527c051e583b902f156c318dfde"><gtr:id>b1c9c527c051e583b902f156c318dfde</gtr:id><gtr:otherNames>Breitsprecher D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1472-6807</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/2E964B49-6FB2-496F-8145-12D6CD335B04"><gtr:id>2E964B49-6FB2-496F-8145-12D6CD335B04</gtr:id><gtr:title>Structural basis of hepatocyte growth factor/scatter factor and MET signalling.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/73099a715c34b49f3fb33f13d128e7cc"><gtr:id>73099a715c34b49f3fb33f13d128e7cc</gtr:id><gtr:otherNames>Gherardi E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/C0B6EDAA-7C4E-4476-B912-74048B7B02BC"><gtr:id>C0B6EDAA-7C4E-4476-B912-74048B7B02BC</gtr:id><gtr:title>Engineering the NK1 fragment of hepatocyte growth factor/scatter factor as a MET receptor antagonist.</gtr:title><gtr:parentPublicationTitle>Journal of molecular biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/4da106ff90ea5e7644df5f6705e72dd7"><gtr:id>4da106ff90ea5e7644df5f6705e72dd7</gtr:id><gtr:otherNames>Youles M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0022-2836</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/2118EFB8-EF9F-408A-80C7-9DEFE2D7FBFF"><gtr:id>2118EFB8-EF9F-408A-80C7-9DEFE2D7FBFF</gtr:id><gtr:title>Insights into the structure/function of hepatocyte growth factor/scatter factor from studies with individual domains.</gtr:title><gtr:parentPublicationTitle>Journal of molecular biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/6c650ec84f5388b2c7fc639f60cd4d40"><gtr:id>6c650ec84f5388b2c7fc639f60cd4d40</gtr:id><gtr:otherNames>Holmes O</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0022-2836</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/C2890884-8BAD-4F05-BE1E-E389F5F71D59"><gtr:id>C2890884-8BAD-4F05-BE1E-E389F5F71D59</gtr:id><gtr:title>Structural basis for agonism and antagonism of hepatocyte growth factor.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/bb3a4c4aac6c39218e08d4481cd8d8dc"><gtr:id>bb3a4c4aac6c39218e08d4481cd8d8dc</gtr:id><gtr:otherNames>Tolbert WD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/F6F3FDD3-164E-4FA5-9B32-A52CF7B43310"><gtr:id>F6F3FDD3-164E-4FA5-9B32-A52CF7B43310</gtr:id><gtr:title>Protein engineered variants of hepatocyte growth factor/scatter factor promote proliferation of primary human hepatocytes and in rodent liver.</gtr:title><gtr:parentPublicationTitle>Gastroenterology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/b90fcb86f8ff0ef88ec4421190f7ff22"><gtr:id>b90fcb86f8ff0ef88ec4421190f7ff22</gtr:id><gtr:otherNames>Ross J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0016-5085</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/98C6307D-38D8-4EBC-8A31-AD430F1B7AB0"><gtr:id>98C6307D-38D8-4EBC-8A31-AD430F1B7AB0</gtr:id><gtr:title>A mechanistic basis for converting a receptor tyrosine kinase agonist to an antagonist.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/bb3a4c4aac6c39218e08d4481cd8d8dc"><gtr:id>bb3a4c4aac6c39218e08d4481cd8d8dc</gtr:id><gtr:otherNames>Tolbert WD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G9704528</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>F3822669-BB5A-4BB4-BAE0-DCB9DE36E092</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Generic Health Relevance</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CF950C9A-DB16-4E23-8AEB-94548777BCA1</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>1.1  Normal biological development and functioning</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>